Novartis Snaps Up KRAS Inhibitor R&D
Difficult-To-Target Oncogenic Proteins Yield To Drug Discovery
Novartis has taken an option on novel inhibitors of the KRAS cell signaling pathway while it funds the drug discovery research at the Cancer Research UK’s Beatson Institute.
You may also be interested in...
Merck & Co. is paying $50m up front to combine preclinical KRAS-target cancer compound pipelines with Astex and Taiho, both affiliates of Japan’s Otsuka. The two biotechs could realize up to $2.5bn in earnouts under the collaboration.
The small biotech firm has traded higher in recent months based on Amgen’s AMG 510 results to date, and saw its share price soar based on initial efficacy data for MRTX849 in lung and colorectal cancers.